Quantitative Systematic Strategies LLC Reduces Holdings in Iovance Biotherapeutics Inc (IOVA)

Quantitative Systematic Strategies LLC cut its holdings in Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 7.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,157 shares of the biotechnology company’s stock after selling 918 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in Iovance Biotherapeutics were worth $116,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Iovance Biotherapeutics by 66.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,374 shares of the biotechnology company’s stock worth $137,000 after buying an additional 6,162 shares during the period. RA Capital Management LLC raised its holdings in Iovance Biotherapeutics by 142.6% during the 4th quarter. RA Capital Management LLC now owns 2,720,452 shares of the biotechnology company’s stock worth $24,076,000 after buying an additional 1,599,299 shares during the period. NF Trinity Capital Hong Kong Ltd raised its holdings in Iovance Biotherapeutics by 83.0% during the 4th quarter. NF Trinity Capital Hong Kong Ltd now owns 228,442 shares of the biotechnology company’s stock worth $2,022,000 after buying an additional 103,588 shares during the period. Vanguard Group Inc raised its holdings in Iovance Biotherapeutics by 8.1% during the 3rd quarter. Vanguard Group Inc now owns 4,048,782 shares of the biotechnology company’s stock worth $45,550,000 after buying an additional 302,649 shares during the period. Finally, Teachers Advisors LLC raised its holdings in Iovance Biotherapeutics by 27.6% during the 3rd quarter. Teachers Advisors LLC now owns 727,043 shares of the biotechnology company’s stock worth $8,179,000 after buying an additional 157,427 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

NASDAQ:IOVA opened at $10.84 on Friday. Iovance Biotherapeutics Inc has a fifty-two week low of $7.26 and a fifty-two week high of $18.25.

Several analysts have issued reports on the company. Oppenheimer restated a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, March 19th. ValuEngine upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. BidaskClub upgraded Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, Zacks Investment Research upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Friday, January 4th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.86.

ILLEGAL ACTIVITY WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/quantitative-systematic-strategies-llc-reduces-holdings-in-iovance-biotherapeutics-inc-iova.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Recommended Story: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics Inc (NASDAQ:IOVA).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.